Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

FDA issues EUA for Moderna's mRNA-1273 for COVID-19

Dec. 21, 2020

Soricimed to explore utility of SOR-C13 for COVID-19

Dec. 21, 2020

FDA clears IND for AlloVir's ALVR-106 to treat severe respiratory viral infections

Dec. 18, 2020

Shionogi initiates phase I/II study in Japan with COVID-19 vaccine candidate

Dec. 18, 2020

Abpro initiates phase II/III registrational studies of ABP-300 as treatment of COVID-19

Dec. 17, 2020

First participant dosed in phase I study of TBAJ-587

Dec. 17, 2020

Valneva opens phase I/II study of COVID-19 vaccine candidate VLA-2001

Dec. 16, 2020

First patients enrolled in phase IIb study of rNAPc2 for COVID-19

Dec. 16, 2020

Initiation of first-in-human study of CVB vaccine candidate, PRV-101

Dec. 16, 2020

Positive interim data presented from phase IIb portion of ifenprodil COVID Study

Dec. 16, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...